In short
This article examines two clinical trials investigating the use of live bacterial strains for treating different intestinal conditions. The first trial focuses on preventing recurrent Clostridioides difficile infection using VE303, while the second trial evaluates VE202 for treating mild to moderate ulcerative colitis. Both trials utilize capsules containing multiple strains of live bacteria to potentially improve gut health and manage these conditions.
What is CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE?
CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE is a type of beneficial bacteria that is being studied as a potential treatment for certain gastrointestinal conditions. It is part of a group of bacteria known as live biotherapeutic products (LBPs), which are living microorganisms used to prevent, treat, or cure diseases in humans.
This particular strain is one of several bacterial strains included in two investigational drugs called VE303 and VE202. These drugs are being developed by Vedanta Biosciences, Inc. to help restore balance to the gut microbiome, which is the community of microorganisms living in our digestive tract.
How does it work?
The exact mechanism of action is still being studied, but it's believed that CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE and other bacterial strains in VE303 and VE202 work by:
- Colonizing the gut and helping to restore a healthy balance of bacteria
- Competing with harmful bacteria for resources and space in the intestines
- Potentially producing beneficial substances that support gut health
- Interacting with the immune system to promote a healthy immune response
By promoting a healthy gut microbiome, these bacteria may help improve various gastrointestinal conditions.
What conditions does it treat?
CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE is currently being studied as part of two different treatments:
- VE303 for Clostridioides difficile infection (CDI): This drug is being investigated for the prevention of recurrent C. difficile infection. C. difficile is a type of bacteria that can cause severe diarrhea and other intestinal problems, especially after antibiotic use.
- VE202 for ulcerative colitis: This drug is being studied for the treatment of mild-to-moderate ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum.
Current Clinical Trials
Two major clinical trials are currently underway to study the effectiveness and safety of treatments containing CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE:
- VE303 for C. difficile infection: This is a Phase 3 study called the RestoratiVE303 Study. It aims to evaluate whether VE303 can prevent recurrent C. difficile infection in patients who have recently been treated for a C. difficile infection.
- VE202 for ulcerative colitis: This is a Phase 2 study investigating whether VE202 can improve symptoms and promote healing in patients with mild-to-moderate ulcerative colitis.
Both studies are randomized, double-blind, and placebo-controlled, which means that participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.
How is it administered?
In both clinical trials, the treatments containing CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE are administered orally in the form of capsules. The specific dosing regimens are as follows:
- VE303 for C. difficile infection: Participants take the capsules daily for 14 consecutive days.
- VE202 for ulcerative colitis: Participants take the capsules for 8 weeks.
Potential Side Effects
As these treatments are still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are carefully monitoring participants for any adverse events. Some general considerations for live bacterial treatments include:
- Mild digestive symptoms like gas or bloating as the gut adjusts to the new bacteria
- Potential risk of infection, especially in people with weakened immune systems
- Possible interactions with other medications, particularly antibiotics
It's important to note that the clinical trials have specific inclusion and exclusion criteria to ensure the safety of participants. For example, people with certain medical conditions or those taking specific medications may not be eligible to participate.
Conclusion
CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE is a promising component of new treatments being developed for C. difficile infection and ulcerative colitis. While the research is still ongoing, these live biotherapeutic products represent an exciting new approach to treating gastrointestinal conditions by harnessing the power of beneficial bacteria. As always, it's important to consult with a healthcare provider about the most appropriate treatments for your individual situation.